Trial Profile
A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel as First-Line Treatment of Patients With Her2-Positive Progressive Or Recurrent Locally Advanced Or Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Docetaxel; Trastuzumab
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Roche
- 18 Jan 2017 Status changed from completed to discontinued.
- 04 Nov 2016 Status changed from active, no longer recruiting to completed.
- 29 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.